Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TPI-1062
JNJ-39823277 · 1 trial · 1 indication
The Cmax is defined as maximum observed analyte concentration.
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
The AUClast is area under the plasma concentration-time curve from time zero to the last quantifiable concentration.
The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of Area under Curve (AUC) last and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.
The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda\[z\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
The Cmax is defined as maximum observed analyte concentration.
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
The AUClast is area under the plasma concentration-time curve from time zero to the last quantifiable concentration.
The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of Area under Curve (AUC) last and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.
The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda\[z\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | Participants will receive 100 mg JNJ-39823277 under fed (after a high fat) condition. |
| Treatment B | EXPERIMENTAL | Participants will receive 100 mg JNJ-39823277 under fasted condition. |
| Name | Type | Description |
|---|---|---|
| JNJ-39823277 | DRUG | Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose. |
Inclusion Criteria: * Participant must be a healthy male or non-lactating healthy female * Agrees to protocol-defined use of effective contraception * If a woman, must have a negative serum ß-human chorionic gonadotropin (ß-hCG) pregnancy test at screening and on Day -1 of each treatment period * A...
JNJ-39823277 is an investigational small molecule developed by Johnson & Johnson. It has been studied in a Phase 1 clinical trial in healthy participants, and no therapeutic indication for the compound has been disclosed. It is not an approved medicine and remains in early clinical development.
JNJ-39823277 is developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 study of the compound conducted in the United States.
JNJ-39823277 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials of the compound are currently listed. It is an investigational agent and has not been approved by the FDA for any use.
JNJ-39823277 has been studied in one clinical trial, NCT02103985, titled A Study of Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Participants. The Phase 1 trial enrolled 32 healthy volunteers in the United States, was controlled and randomized, and has been completed.
Yes. JNJ-39823277 is also known as TPI-1062, and the two names refer to the same investigational small molecule. The alternative name appears in the title of its completed Phase 1 trial, NCT02103985, which evaluated the effect of food on the pharmacokinetics of a single dose in healthy participants.